Global Chronic Myeloid Leukemia Treatment Market Report 2024: Market Size, CAGR, Lucrative Segments And Top Regions| Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co.

Overview and Scope
Chronic myeloid leukemia (CML) is a type of cancer that affects the bone marrow and blood cells and is characterized by the overproduction of abnormal white blood cells known as granulocytes. Chronic myeloid leukemia (CML) treatment aims to control the disease, reduce symptoms and improve the quality of life for patients suffering from the disease.

Sizing and Forecast
The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $8.58 billion in 2023 to $9.2 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $12.06 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/chronic-myeloid-leukemia-treatment-global-market-report

Segmentation & Regional Insights
The chronic myeloid leukemia treatment market covered in this report is segmented –

1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By End-User: Hospitals; Specialty Clinics; Other End-Users

North America was the largest region in the chronic myeloid leukemia treatment market in 2023. The regions covered in chronic myeloid leukemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12915&type=smp

Major Driver Impacting Market Growth
The increasing incidences of myeloid leukemia are expected to propel the growth of the chronic myeloid leukemia (CML) treatment market going forward. Myeloid leukemia is a type of cancer that originates in the bone marrow and affects the cells responsible for producing various kinds of blood cells. Chronic myeloid leukemia (CML) treatment aims to improve bone marrow function by targeting the root cause of leukemia to reduce the risk of complications with low blood cell counts, reduce the need for chemotherapy and transplants and improve the survival rates for people with myeloid leukemia. For instance, in January 2023, according to the estimates of the American Cancer Society, a US-based voluntary health organization, there were about 20,380 cases and 11,310 deaths of acute myeloid leukemia (AML) in adults in 2023. Therefore, the increasing incidences of myeloid leukemia drive the chronic myeloid leukemia (CML) treatment market.

Key Industry Players
Major players in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

The chronic myeloid leukemia treatment market report table of contents includes:

1. Executive Summary
2.Chronic Myeloid Leukemia Treatment Market Characteristics
3.Chronic Myeloid Leukemia Treatment Market Trends And Strategies
4.Chronic Myeloid Leukemia Treatment Market analysis
5.Chronic Myeloid Leukemia Treatment Market Size And Growth
6.Chronic Myeloid Leukemia Treatment Segmentation
7.Chronic Myeloid Leukemia Treatment Regional And Country Analysis
.
.
.
27.Chronic Myeloid Leukemia Treatment Competitive Landscape And Company Profiles
28.Chronic Myeloid Leukemia Treatment Key Mergers And Acquisitions
29.Chronic Myeloid Leukemia Treatment Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Pfizer Inc.
• Johnson and Johnson Limited
• F. Hoffmann-La Roche AG
• AbbVie Inc.
• Novartis AG

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model